Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
MilliporeSigma has acquired all ownership rights to the ProcessPad™ platform from Simplyfeye Softwares Private Limited. The agreement includes the transfer of all copyrights and relevant intellectual property related to this software platform.
Acacia Pharma Group plc announces its unaudited interim results for the six-month period ended 30 June 2019.
Polyphor AG announced that the company will present at the 21st Annual H.C. Wainwright Global Investment Conference, taking place September 8-10, 2019 in New York City.
Late Wednesday, the company said it is looking to facilitate the sale of its business products in development, as well as its technology.
Biofidelity Ltd announces it has secured £0.75 million seed financing, following its formation earlier this year.
Polyphor AG focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics, publishes today its financial results for the first half of 2019 and announces a realignment of the strategy.
Massachusetts Life Sciences Center awards funding to support early-stage growth across major sectors
MLSC’s Milestone Achievement Program awards more than $1.9 million to 10 companies representing all major life sciences sectors
Robocath announces that it has raised €5 million to support the rollout of its robotic platform in strategic European target markets.
Forbion announces that it has participated in a £100 million Series B financing of Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies.
Financing will support continued clinical development of gene therapies and surgical delivery systems for retinal diseases